WHO. Guidelines on evaluation of biosimilars Replacement of Annex 2 of WHO technical report series, No. 977. 2022. https://cdn.who.int/media/docs/default-source/biologicals/annex-3---who-guidelines-on-evaluation-of-biosimilars---sj-ik-5-may-2022.pdf?sfvrsn=9b2fa6d2_1&download=true. Accessed 31 Jan 2023.

US FDA. Evaluation of therapeutic equivalence. 2023. chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.fda.gov/media/160054/download. Accessed 07 Oct 2023.

WHO. WHO TRS No. 1003, vol. Fifty firs. 2017. https://www.who.int/publications-detail-redirect/9789241210034

Formulary NI. Items unsuitable for generic prescribing. 2023. https://niformulary.hscni.net/prescribing-newsletters/generic-prescribing/. Accessed 24 Nov 2023

Zagalo DM, Sousa J, Simões S. Quality by design (QbD) approach in marketing authorization procedures of non-biological complex drugs: a critical evaluation. Eur J Pharm Biopharm. 2022;178(April):1–24. https://doi.org/10.1016/j.ejpb.2022.07.014.

Article  CAS  PubMed  Google Scholar 

EMA, “Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU. 2022. www.ema.europa.eu/contact. Accessed 01 Oct 2022.

Nederlands Huisartsen Genootschap. Medicines that you should not switch brands of. 2024. https://richtlijnen.nhg.org//files/2024-01/Medicijnen waarbij je niet van merk mag wisselen (2024).pdf

Nederlands Huisartsen Genootschap. Medicines where you may only switch brands with supervision. 2024. https://richtlijnen.nhg.org//files/2024-01/Medicijnen waarbij je alleen met begeleiding van merk mag wisselen (2024).pdf

AEMPS. Non-substitutable medicines. 2024. https://www.aemps.gob.es/medicamentos-de-uso-humano/medicamentos-no-sustituibles/. Accessed 30 Aug 2024.

U. S. Congress. Hatch-Waxman-Act. USA. 1984. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/hatch-waxman-letters

Pejčić Z, Vučenović VT, Miljković B. Review of lists and recommendations for interchangeability of medicines across selected European countries. 2024; pp. 540–55.

INESSS. State of safety of switching biologics and their interchangeability. 2020.

Kim J, Arias J, Gavura S. National and international policies on the use of biosimilars an environmental scan. Can J Heal Technol. 2024;5:35. https://doi.org/10.51731/CJHT.2024.927.

Article  Google Scholar 

CADTH. International policies on the appropriate use of biosimilar drugs. 2023. https://www.cadth.ca/sites/default/files/pdf/es0333_international-policies-on-use-of-biosimilar-drugs.pdf. Accessed 25 Jul 2023

The Ministery of the Economy Finance and Recovery and the Ministery of Solidarity and Health, Order of April 12, 2022 establishing the list of similar biological groups that can be substituted by the community pharmacist and the conditions of substitution and information for the prescriber and the patient as provided for in 2° of Article L. 5125–2. France. 2022. https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000045571129

F. and I. and D. S. and the M. of H. and P. The Ministery of Economy, Order of December 18, 2023 supplementing the order of April 12, 2022 establishing the list of similar biological groups that can be substituted by the community pharmacist and the conditions of substitution and information for the prescriber and the patie. France. 2023. https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000048621757

Comité Conditions de mise en oeuvre de la substitution des médicaments biologiques similaires. https://ansm.sante.fr/evenements/comite-conditions-de-mise-en-oeuvre-de-la-substitution-des-medicaments-biologiques-similaires-2. Accessed 24 Aug 2024.

DeutschesApothekenPortal. Austausch von biotechnologisch hergestellten Arzneimitteln. DeutschesApothekenPortal. https://www.deutschesapothekenportal.de/rezept-retax/retax-arbeitshilfen/biologicals/austausch-anlage-1-rv/

DeutschesApothekenPortal. Austausch Anlage 1 RV—DeutschesApothekenPortal. https://www.deutschesapothekenportal.de/rezept-retax/retax-arbeitshilfen/biologicals/austausch-anlage-1-rv/. Accessed 25 Aug 2024.

Bundsausschuss G. Exchange of biotechnologically produced biological finished medicinal products by pharmacies for parenteral preparations for direct medical use—Section 40b. Germany. 2023. https://www.g-ba.de/beschluesse/6045/

Swedish Medical products Agency. Substitutability list. https://www.lakemedelsverket.se/sv/behandling-och-forskrivning/utbytbara-lakemedel/utbytbarhetslista#hmainbody7

Direktoratet for medisinske Produkter. Biosimilar medicines can be exchanged in pharmacies. https://www.dmp.no/nyheter/biotilsvarende-legemidler-kan-byttes-i-apotek. Accessed 30 Aug 2024.

Direktoratet for medisinske Produkter, “Exchange lists. https://www.dmp.no/nyheter?category=Byttelisteoppdateringer. Accessed 30 Aug 2024.

The Medical Council. The Danish Medicines Council’s assessment of biosimilar medicines. 2024. https://medicinraadet.dk/om-os/medicinradets-arbejde/biosimilaere-laegemidler. Accessed 09 Sept 2024.

Agenzia Italiana del Farmaco (AIFA). Secondo position paper AIFA sui Farmaci Biosimilari, Aifa. 2018. pp. 1–28. http://www.agenziafarmaco.gov.it/sites/default/files/2_Position-Paper-AIFA-Farmaci-Biosimilari.pdf

Agenzia Italiana del Farmaco (AIFA). Biosimilar drugs. https://www.aifa.gov.it/farmaci-biosimilari. Accessed 30 Aug 2024.

HPRA. Guide to biosimilars for healthcare professionals. Heal. Prod. Regul. Auth. Irel. 2020. https://www.hpra.ie/docs/default-source/publications-forms/guidance-documents/guide-to-biosimilars-for-healthcare-professionals-v3.pdf?sfvrsn=22

FAMHP. Biosimilars | FAMHP. https://www.famhp.be/en/human_use/medicines/medicines/MA_procedures/types/Biosimilars. Accessed 02 Sept 2024

La Noce A, Ernst M. Switching from reference to biosimilar products: an overview of the European approach and real-world experience so far. EMJ. 2018;3(3):74–81.

Google Scholar 

Druedahl LC, et al. Interchangeability of biosimilars: a study of expert views and visions regarding the science and substitution. PLoS ONE. 2022;17(1):1–13. https://doi.org/10.1371/journal.pone.0262537.

Article  CAS  Google Scholar 

Carver KH, Elikan J, Lietzan E. An unofficial legislative history of the biologics price competition and innovation act of 2009. Food Drug law. 2010;65(4):617–818.

Google Scholar 

US FDA.Considerations in demonstrating interchangeability with a reference product-guidance for industry. US Food Drug Administration. 2019.

Humphreys S. Understanding interchangeable biosimilars at the federal and state levels. Evidence-Based Oncol. 2023;29(7):545–8.

Google Scholar 

Cardinal Health. State laws for biosimilar interchangeability. https://www.cardinalhealth.com/en/product-solutions/pharmaceutical-products/biosimilars/state-regulations-for-biosimilar.html. Accessed 30 Aug 2024

McKinley L, Kelton JM, Popovian R. Sowing confusion in the field: the interchangeable use of biosimilar terminology. Curr Med Res Opin. 2019;35(4):619–21. https://doi.org/10.1080/03007995.2018.1560223.

Article  PubMed  Google Scholar 

Christl L, Lim S, Biologics T. Biosimilar FDA slides : scientific concepts, clinical use, and practical considerations overview. chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.fda.gov/media/122832/download. Accessed 24 Nov 2023.

Federal Trade Commission (FTC) and Food and Drug Administration (FDA). Joint FDA-FTC statement on competition in the biologic marketplace. 2020; 03072018: pp. 1–6. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/citizen-petitions-and-petitions-stay

Mehr SR, Zimmerman MP. Is a biologic produced 15 years ago a biosimilar of itself today? Am Heal Drug Benefits. 2016;9(9):515–8.

Google Scholar 

U.S. Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), and Center for Biologics Evaluation and Research (CBER). Considerations in demonstrating interchangeability with a reference product-update. FDA. 2024; 23.

US FDA. Guidance for industry statistical approaches to establishing bioequivalence. Analysis. 2023. http://www.lexjansen.com/pharmasug/2008/sp/sp04.pdf. Accessed 24 Nov 2023.

Niazi SK. Handbook of bioequivalence testing. Baco Raton: CRC Press; 2007. https://doi.org/10.3109/9780849383595.

Book  Google Scholar 

Feagan BG. The challenges of switching therapies in an evolving multiple biosimilars landscape: a narrative review of current evidence. Adv Ther. 2020. https://doi.org/10.1007/s12325-020-01472-1.

Article  PubMed  PubMed Central  Google Scholar 

Barbier L, Simoens S, Vulto AG, Huys I. European stakeholder learnings regarding biosimilars: Part II—improving biosimilar use in clinical practice. BioDrugs. 2020;34(6):797–808. https://doi.org/10.1007/s40259-020-00440-z.

Article  PubMed  PubMed Central  Google Scholar 

Sani NM, Aziz Z, Kamarulzaman A. Use of biosimilars: a systematic review of published position statements and recommendations from health organisations and societies. BioDrugs. 2024;38(3):405–23. https://doi.org/10.1007/s40259-024-00649-2.

Article  Google Scholar 

Sullivan E, Piercy J, Waller J, Black CM, Kachroo S. Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn’s disease across Germany. PLoS ONE. 2017;12(4):1–14. https://doi.org/10.1371/journal.pone.0175826.

Article  CAS  Google Scholar 

Goncalves J, et al. Position paper from the portuguese association of hospital pharmacists for biosimilar therapeutic antibodies. J Clin Pharm Ther. 2017;42(2):239–43. https://doi.org/10.1111/jcpt.12477.

Article  CAS  PubMed  Google Scholar 

Kurki P, Barry S, Bourges I, Tsantili P, Wolff-Holz E. Safety, immunogenicity and interchangeability of biosimilar monoclonal antibodies and fusion proteins: a regulatory perspective. Drugs. 2021;81(16):1881–96. https://doi.org/10.1007/s40265-021-01601-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Herndon TM, et al. Safety outcomes when switching between biosimilars and reference biologics: a systematic review and meta-analysis. PLoS ONE. 2023. https://doi.org/10.1371/JOURNAL.PONE.0292231.

Article  PubMed  PubMed Central  Google Scholar 

ICMRA. ICMRA statement on international collaboration to enable real-world evidence (RWE) for regulatory decision-making 1. Background. 2023. https://icmra.info/drupal/sites/default/files/2022-07/icmra_statement_on_rwe.pdf. Accessed 31 Jan 2023.

EMA. Technical workshop on real-world metadata for regulatory purposes. 2023. https://www.ema.europa.eu/en/events/technical-workshop-real-world-metadata-regulatory-purposes. Accessed 31 Jan 2023.

Bakker E, Plueschke K, Jonker CJ, Kurz X, Starokozhko V, Mol PGM. Contribution of real-world evidence in european medicines agency’s regulatory decision making. Clin Pharmacol Ther. 2022;113(1):135–51. https://doi.org/10.1002/cpt.2766.

Article  PubMed  PubMed Central  Google Scholar 

Nava-Parada P, Shelbaya A, Nabhan C. Rituximab biosimilars in hematologic malignancies: the need for a real-world approach. Futur Oncol. 2020;16(26):2017–27. https://doi.org/10.2217/fon-2020-0131.

Article  CAS  Google Scholar 

Serrano L, et al. Comparative effectiveness and drug survival of biosimilar infliximab CPT-13 vs. reference infliximab in inflammatory bowel disease: a retrospective cohort study. Gastroenterol Hepatol. 2024;47:553–61.

Article  Google Scholar 

J. Bryan. Characterizing RWD quality and relevancy for regulatory purposes. Duke University. 2018. https://healthpolicy.duke.edu/sites/default/files/2020-03/characterizing_rwd.pdf

Cheung WY, et al. Real-world safety and effectiveness of a bevacizumab biosimilar (ABP 215) in metastatic colorectal cancer patients in Canada. Clin Colorectal Cancer. 2024;23(1):46-57.e4. https://doi.org/10.1016/j.clcc.2023.10.007.

Article  PubMed  Google Scholar 

International Society of Pharmacoepidiology. Guidelines for good pharmacoepidemiology practices (GPP). 2015. https://www.pharmacoepi.org/resources/policies/guidelines-08027/#:~:text=Pharmacoepidemiologic studies provide valuable information, and interpretation of pharmacoepidemiologic research.

Nancy P, Dreyer A, et al. GRACE principles: recognizing high-quality observational studies of comparative effectiveness. Am J Manag Care. 2010;16(6):22010.

Google Scholar 

Rémuzat C, Dorey J, Cristeau O, Ionescu D, Radière G, Toumi M. Key drivers for market penetration of biosimilars in Europe. J Mark Access Heal Policy. 2017;5(1):1272308. https://doi.org/10.1080/20016689.2016.1272308.

Article  Google Scholar 

Li E, Liu J, Ramchandani M. A framework for integrating biosimilars into the didactic core requirements of a doctor of pharmacy curriculum. Am J Pharm Educ. 2017. https://doi.org/10.5688/ajpe81357.

Article